Olaparib + bevacizumab Emerging Drug Insight and Market Forecast - 2032

“Olaparib ± bevacizumab Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Olaparib ± bevacizumab for Metastatic Colorectal Cancer in the 7MM. A detailed picture of the Olaparib ± bevacizumab for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Olaparib ± bevacizumab for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Olaparib ± bevacizumab market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

LYNPARZA (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to DNA single-strand breaks, the stalling of replication forks, their collapse, and the generation of DNA double-strand breaks, and cancer cell death. LYNPARZA is being tested in a range of tumor types with defects and dependencies in the DDR.

LYNPARZA, jointly developed and commercialized by AstraZeneca and Merck, is currently approved for certain types of advanced ovarian, breast, and pancreatic cancers and has a broad and advanced clinical trial development program. AstraZeneca and Merck are working together to understand how it may affect multiple PARP-dependent tumors as a monotherapy and in combination across multiple cancer types.

Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in the microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues.

Merck is currently conducting a Phase III trial (NCT04456699) of olaparib alone or in combination with bevacizumab for treating mCRC for 1L maintenance.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Olaparib ± bevacizumab description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Olaparib ± bevacizumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Olaparib ± bevacizumab research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Olaparib ± bevacizumab.
• The report contains forecasted sales of Olaparib ± bevacizumab for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Olaparib ± bevacizumab in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Olaparib ± bevacizumab Analytical Perspective

In-depth Olaparib ± bevacizumab Market Assessment

This report provides a detailed market assessment of Olaparib ± bevacizumab in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for Olaparib ± bevacizumab.

Olaparib ± bevacizumab Clinical Assessment

The report provides the clinical trials information of Olaparib ± bevacizumab in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Olaparib ± bevacizumab dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Olaparib ± bevacizumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Olaparib ± bevacizumab in Metastatic Colorectal Cancer.
• This in-depth analysis of the forecasted sales data of Olaparib ± bevacizumab will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Olaparib ± bevacizumab in Metastatic Colorectal Cancer.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Olaparib ± bevacizumab?
• What is the clinical trial status of the study related to Olaparib ± bevacizumab in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Olaparib ± bevacizumab development?
• What are the key designations that have been granted to Olaparib ± bevacizumab for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Olaparib ± bevacizumab for Metastatic Colorectal Cancer?
• What are the forecasted sales of Olaparib ± bevacizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Olaparib ± bevacizumab for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?

This product will be delivered within 2 business days.